Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio

Eli Lilly will acquire Centessa for $38 per share in cash plus a contingent value right up to $9/share, valuing the deal at ~$6.3bn upfront and up to ~$7.8bn including milestones. The deal adds Centessa's sleep-wake disorder pipeline and lead asset cleminorexton to Lilly's neuroscience franchise, strengthening its R&D pipeline. The transaction is strategic for Lilly and likely to move LLY and CNTA equity on the terms and potential milestone upside.

Analysis

This deal is less about immediate revenue and more about asymmetric option-value: an incumbent with scale is buying a narrowly de-risked program that can be accelerated through existing commercial and regulatory channels. Expect the real value capture to come from shortened time-to-market, additional label or indication expansion, and access to larger prescriber networks — effects that play out over 2–5 years rather than quarters.

Second-order winners include CMOs and API suppliers that serve sleep/neuroscience small-molecule manufacturing; consolidating development into a single large sponsor tends to concentrate volume and raise bargaining power, pressuring smaller rivals that relied on scale from the target. Conversely, mid-sized pure-play neurobiotechs without a broad commercial franchise face increased pressure to either niche down or seek partnering sooner, which can compress valuations in the next 6–18 months.

Tail risks are dominated by binary clinical and regulatory outcomes and integration distraction. Milestone-linked payments shift downside to the buyer but retain binary payout risk tied to specific readouts; a regulatory surprise or slower-than-expected uptake would meaningfully compress the acquirer’s near-term FCF and could delay other neuroscience investments for 12–24 months. The most likely catalyst sequence: upcoming pivotal readouts (6–24 months), regulatory interactions (12–36 months), then full commercial rollouts (24–60 months).

Key Decisions for Investors

• Merger-arb (CNTA): If the cash spread to implied takeover value is >1–3%, size a long position in CNTA to capture deal close within expected regulatory timeline; hedge event risk by keeping position sized to <3% of portfolio. Expect 5–15% IRR to close if no hostile regulatory issues; downside is deal termination (binary loss capped to full equity position).
• Core long (LLY): Add a 6–18 month tactical overweight in LLY (2–4% portfolio) to capture upside from pipeline acceleration and cross-selling synergies. Use covered-call overlays (sell 3–9 month OTM calls to finance ~50–75bps of position carry) to protect against near-term dilution sentiment; downside scenario is a 6–12% contraction in stock if clinical/regulatory setbacks materialize.
• CVR-specific trade: If milestone instruments separate and trade, sell a portion of CVR exposure sizeably (short 20–30% of CVR notional) to monetize the market’s tendency to overprice low-probability payoffs; this is a short-volatility, event-risk trade—target small position sizes given binary loss potential.
• Risk hedge: Buy 6–18 month put protection on LLY (~3–5% notional) or reduce cyclical exposure elsewhere to fund it. This limits portfolio drawdown from the acquirer’s potential FCF hit if multiple neuroscience programs are deprioritized following integration.